Table 5.

Third line treatment proportions and associated confidence intervals

Line 3 treatment	Flatiron drug proportion ± confidence interval	McKesson drug proportion ± confidence interval	MarketScan drug proportion ± confidence interval	PharMetrics+ drug proportion ± confidence interval	Social media drug proportion ± confidence interval
Pembrolizumab	15.3% ± 3.9%	22.7% ± 10.1%	4.1% ± 1.7%	18.2% ± 6.1%	4.1% ± 4.6%
Dabrafenib and Trametinib	12.9% ± 3.6%	0% ± 0%	7.0% ± 2.2%	13.0% ± 5.3%	9.6% ± 6.8%
Nivolumab	12.0% ± 3.5%	22.7% ± 10.1%	5.3% ± 1.9%	16.9% ± 5.9%	19.2% ± 9.0%
Ipilimumab	9.2% ± 3.1%	9.1% ± 6.9%	7.0% ± 2.2%	10.4% ± 4.8%	16.4% ± 8.5%
Ipilimumab and Nivolumab	8.9% ± 3.1%	18.2% ± 9.3%	2.5% ± 1.4%	2.6% ± 2.5%	12.3% ± 7.5%
Temozolomide	4.9% ± 2.3%	0% ± 0%	3.3% ± 1.5%	5.2% ± 3.5%	1.4% ± 2.7%

Note: Bold values indicate where social media estimates overlap with a database.